October 1, 2015
Evonik to build additional methionine plant in Singapore
![](/cps/images/2015/october/photo-15-10-1aa.gif)
Evonik Industries has started the planning stage for the construction of an additional world-scale plant complex in Singapore.
The facility, which will produce the amino acid DL-methionine for animal nutrition, will have an annual production capacity of 150,000 tonnes and is expected to start operations in 2019. It still requires authorisation from the Evonik committees.
The growth of the DL-methionine business is said to be driven by global megatrends of health and nutrition.
"We are convinced that the market for DL-methionine will continue to show dynamic
growth, and we want to contribute to meeting the global demand for this product, which is indispensable for efficient and sustainable animal nutrition worldwide," says Klaus Engel, the chairman of the executive board of Evonik.
The company sells DL-methionine under the brand name MetAMINO®.
Evonik''s most recent methionine plant took up its operations in Singapore in the fourth quarter of 2014 after a two-year construction period and operations are utilised according to plan (http://www.cnchemicals.com/).
"The new complex will allow us to accompany market growth and further strengthen customer relations. As a reliable partner to our customers, we are of the strong conviction to realise this project in the given time frame as well," says Dr. Reiner Beste, the Chairman of the Board of Management at Evonik Nutrition & Care GmbH.
In its new, backward-integrated production complex, the company will also produce all associated strategically relevant precursors.
The construction of the plant complex is planned next to the existing methionine plant on Jurong Island in Singapore.